Clinical features and outcomes of patients with myasthenia gravis

References

1. ↵
   1. Ruff RL,
   2. Lisak RP

   (2018) Nature and Action of Antibodies in Myasthenia Gravis. Neurol Clin 36, 275–291.
2. ↵
   1. Zisimopoulou P,
   2. Evangelakou P,
   3. Tzartos J,
   4. Lazaridis K,
   5. Zouvelou V,
   6. Mantegazza R,
   7. et al.

   (2014) A comprehensive analysis of the epidemiology and clinical characteristics of anti-LRP4 in myasthenia gravis. J Autoimmun 52, 139–145.
3. ↵
   1. Grob D,
   2. Brunner N,
   3. Namba T,
   4. Pagala M

   (2008) Lifetime course of myasthenia gravis. Muscle Nerve 37, 141–149.
4. ↵
   1. Heldal AT,
   2. Owe JF,
   3. Gilhus NE,
   4. Romi F

   (2009) Seropositive myasthenia gravis:a nationwide epidemiologic study. Neurology 73, 150–151.
5. ↵
   1. Al-Moallem MA,
   2. Alkali NH,
   3. Hakami MA,
   4. Zaidan RM

   (2008) Myasthenia gravis:presentation and outcome in 104 patients managed in a single institution. Ann Saudi Med 28, 341–345.
6. ↵
   1. Radhakrishnan K,
   2. Thacker AK,
   3. Maloo JC,
   4. Gerryo SE,
   5. Mousa ME

   (1988) Descriptive epidemiology of some rare neurological diseases in Benghazi, Libya. Neuroepidemiology 7, 159–164.
7. ↵
   1. Drachman DB,
   2. Adams RN,
   3. Hu R,
   4. Jones RJ,
   5. Brodsky RA

   (2008) Rebooting the Immune System with High-Dose Cyclophosphamide for Treatment of Refractory Myasthenia Gravis. Ann N Y Acad Sci 1132, 305–314.
8. ↵
   1. Burns TM,
   2. Conaway M,
   3. Sanders DB

   (2010) MG Composite and MG-QOL15 Study Group. The MG Composite: A valid and reliable outcome measure for myasthenia gravis 74, 1434–1440.
9. ↵
   1. Sanders DB,
   2. Tucker-Lipscomb B,
   3. Massey JM

   (2003) A simple manual muscle test for myasthenia gravis:validation and comparison with the QMG score. Ann N Y Acad Sci 998, 440–444.
10. ↵
    1. Alanazy MH,
    2. Abuzinadah AR,
    3. Muayqil T

    (2018) Translation and validation of the arabic version of the revised 15-item myasthenia gravis quality-of-life questionnaire. Muscle Nerve 57, 581–585.
11. ↵
    1. Alanazy MH,
    2. Abuzinadah AR,
    3. Muayqil T

    (2019) Translation and validation of the arabic version of the myasthenia gravis activities of daily living scale. Muscle Nerve 59, 583–586.
12. ↵
    1. Jaretzki A,
    2. Barohn RJ,
    3. Ernstoff RM,
    4. Kaminski HJ,
    5. Keesey JC,
    6. Penn AS,
    7. et al.

    (2000) Myasthenia gravis:recommendations for clinical research standards Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. Neurology 55, 16–23.
13. ↵
    1. Carr AS,
    2. Cardwell CR,
    3. McCarron PO,
    4. McConville J

    (2010) A systematic review of population based epidemiological studies in Myasthenia Gravis. BMC Neurol 10, 46.
14. ↵
    1. Boldingh MI,
    2. Maniaol A,
    3. Brunborg C,
    4. Dekker L,
    5. Lipka A,
    6. Niks EH,
    7. et al.

    (2017) Prevalence and clinical aspects of immigrants with myasthenia gravis in northern Europe. Muscle Nerve 55, 819–827.
15. ↵
    1. Oh SJ

    (2009) Muscle-specific receptor tyrosine kinase antibody positive myasthenia gravis current status. J Clin Neurol Seoul Korea 5, 53–64.
16. ↵
    1. Wolfe GI,
    2. Oh SJ

    (2008) Clinical phenotype of muscle-specific tyrosine kinase-antibody-positive myasthenia gravis. Ann N Y Acad Sci 1132, 71–75.
17. ↵
    1. Andersen JB,
    2. Gilhus NE,
    3. Sanders DB

    (2016) Factors affecting outcome in myasthenia gravis. Muscle Nerve 54, 1041–1049.
18. ↵
    1. Guptill JT,
    2. Sanders DB,
    3. Evoli A

    (2011) Anti-MuSK antibody myasthenia gravis:clinical findings and response to treatment in two large cohorts. Muscle Nerve 44, 36–40.
19. ↵
    1. Engel-Nitz NM,
    2. Boscoe A,
    3. Wolbeck R,
    4. Johnson J,
    5. Silvestri NJ

    (2018) Burden of illness in patients with treatment refractory myasthenia gravis. Muscle Nerve.
20. ↵
    1. Wolfe GI,
    2. Kaminski HJ,
    3. Aban IB,
    4. Minisman G,
    5. Kuo HC,
    6. Marx A,
    7. et al.

    (2016) Randomized Trial of Thymectomy in Myasthenia Gravis. N Engl J Med 375, 511–522.